EWA
RCKT icon

Evolution Wealth Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Evolution Wealth Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60
Closed -$2K – 520
2021
Q3 		$2K Sell
60
-93
-61% -$3.38K ﹤0.01% 652
2021
Q2 		$7K Hold
153
– – ﹤0.01% 463
2021
Q1 		$7K Hold
153
– – ﹤0.01% 486
2020
Q4 		$8K Buy
+153
New +$5.58K ﹤0.01% 381

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Evolution Wealth Advisors's RCKT Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q4 2021, closing a stake of 60 shares — an estimated $2K sold.

Evolution Wealth Advisors first reported a position in RCKT in Q4 2020 and held it in 4 quarters. The position peaked at $8K in Q4 2020. 148 funds tracked by Wall St. Rank hold RCKT as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Rocket Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 60 Rocket Pharmaceuticals shares in Q4 2021, an estimated $2K.
  • Evolution Wealth Advisors first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Evolution Wealth Advisors's Rocket Pharmaceuticals position peaked at $8K in Q4 2020.
  • 148 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.